Physician profile
Ruby Bosquez
NPI 1730890526
$1,013.42
in general payments reported to CMS, 2019-2025
13 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $102 · 2023: $168 · 2024: $350 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $911.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $530.37 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $151.73 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Shield Therapeutics INC | $83.61 | 2023-2024 | Accrufer |
| Pfizer INC. | $48.60 | 2024-2025 | |
| Exact Sciences Corporation | $42.21 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $25.34 | 2025 | |
| Sanofi-Aventis U.S. LLC | $24.19 | 2025 | |
| Janssen Pharmaceuticals, INC | $23.04 | 2024 | Spravato |
| Astellas Pharma US INC | $18.44 | 2025 | Veozah |
| Dynavax Technologies Corporation | $17.83 | 2025 | Heplisav-B |
| Astrazeneca Pharmaceuticals Lp | $17.10 | 2025 | Farxiga |
| Amgen INC. | $17.01 | 2023 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $13.95 | 2025 | Bexsero, Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Bosquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.